Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D

Jessica D Church; Dana Jones; Tamara Flys; Donald Hoover; Natalia Marlowe; Shu Chen; Chanjuan Shi; James R Eshleman; Laura A Guay; J. Brooks Jackson; Newton Kumwenda; Taha E Taha; Susan H Eshleman

doi:10.2353/jmoldx.2006.050148

Back

Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D

Journal article

Open access

Peer reviewed

Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D

Jessica D Church, Dana Jones, Tamara Flys, Donald Hoover, Natalia Marlowe, Shu Chen, Chanjuan Shi, James R Eshleman, Laura A Guay, J. Brooks Jackson, …

The Journal of molecular diagnostics : JMD, Vol.8(4), pp.430-432

09/2006

DOI: 10.2353/jmoldx.2006.050148

PMCID: PMC1867617

PMID: 16931582

Files and links (1)

url

https://doi.org/10.2353/jmoldx.2006.050148View

Published (Version of record) Open Access

Abstract

The US Food and Drug Administration-cleared ViroSeq HIV-1 Genotyping System (ViroSeq) and other population sequencing-based human immunodeficiency virus type 1 (HIV-1) genotyping methods detect antiretroviral drug resistance mutations present in the major viral population of a test sample. These assays also detect some mutations in viral variants that are present as mixtures. We compared detection of the K103N nevirapine resistance mutation using ViroSeq and a sensitive, quantitative point mutation assay, LigAmp. The LigAmp assay measured the percentage of K103N-containing variants in the viral population (percentage of K103N). We analyzed 305 samples with HIV-1 subtypes A, C, and D collected from African women after nevirapine administration. ViroSeq detected K103N in 100% of samples with >20% K103N, 77.8% of samples with 10 to 20% K103N, 71.4% of samples with 5 to 10% K103N, and 16.9% of samples with 1 to 5% K103N. The sensitivity of ViroSeq for detection of K103N was similar for subtypes A, C, and D. These data indicate that the ViroSeq system reliably detects the K103N mutation at levels above 20% and frequently detects the mutation at lower levels. Further studies are needed to compare the sensitivity of different assays for detection of HIV-1 drug resistance mutations and to determine the clinical relevance of HIV-1 minority variants.

Technical Advance

Details

Title: Subtitle: Sensitivity of the ViroSeq HIV-1 Genotyping System for Detection of the K103N Resistance Mutation in HIV-1 Subtypes A, C, and D
Creators: Jessica D Church - From the Department of Pathology
Dana Jones - From the Department of Pathology
Tamara Flys - From the Department of Pathology
Donald Hoover - From the Department of Pathology
Natalia Marlowe - From the Department of Pathology
Shu Chen - From the Department of Pathology
Chanjuan Shi - From the Department of Pathology
James R Eshleman - From the Department of Pathology
Laura A Guay - From the Department of Pathology
J. Brooks Jackson - From the Department of Pathology
Newton Kumwenda - From the Department of Pathology
Taha E Taha - From the Department of Pathology
Susan H Eshleman - From the Department of Pathology
Resource Type: Journal article
Publication Details: The Journal of molecular diagnostics : JMD, Vol.8(4), pp.430-432
Publisher: American Society for Investigative Pathology
DOI: 10.2353/jmoldx.2006.050148
PMID: 16931582
PMCID: PMC1867617
ISSN: 1525-1578
eISSN: 1943-7811
Language: English
Date published: 09/2006
Academic Unit: Pathology; VPMA - Administration
Record Identifier: 9984047636302771

Metrics

18 Record Views

49 Times Cited - Web of Science